The authors report here a patient with adult T‐cell leukemia/lymphoma, who developed paroxysmal nocturnal hemoglobinuria seven years after umbilical cord blood transplantation.
[European Journal of Haematology]
1254621 62HJFY6I items 1 apa default asc 1
Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
[Gilead Sciences, Inc.]
Analysis of a rare clinical sample of EBV-positive DLBCL, in combination with a NOD/SCID mouse xenograft model, confirmed the effect of IL-21 on the proliferation of EBV-positive diffuse large B cell lymphoma cells.
Investigators assessed the hematopoietic stem cell content within the CD34+ fraction of graft samples from three groups of patients: 1-Good Mobilizer patients receiving G-CSF only, 2-Poor Mobilizer (PM) patients receiving G-CSF only, 3-PM patients receiving G-CSF + Plerixafor.
1254621 84W74789 items 1 apa default asc 1
Bristol Myers Squibb announced that the European Medicines Agency has validated its Marketing Authorization Application for lisocabtagene maraleucel, an investigational CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B after at least two prior therapies.
[Bristol Myers Squibb]
Investigators demonstrated that while PRDM15 was largely dispensable for mouse adult somatic cell homeostasis in vivo, it played a critical role in B-cell lymphomagenesis.
6445212 RYP646WW items 1 apa default asc 1
The authors performed a nationwide retrospective study of graft-versus-host disease (GvHD)-free, relapse-free survival of patients with allogeneic hematopoietic stem cell transplantation (HSCT)-treated adult T-cell leukemia/lymphoma.
[Bone Marrow Transplantation]
1254621 9WZ2C9UR items 1 apa default asc 1
Merck announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
Fate Therapeutics, Inc. announced that the FDA has cleared the company’s Investigational New Drug application for FT819, an off-the-shelf allogeneic chimeric antigen receptor T-cell therapy targeting CD19+ malignancies.
[Fate Therapeutics, Inc.]
Researchers integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings experimentally.
1254621 VPBSC72E items 1 apa default asc 1
Investigators showed that the SRC-family tyrosine kinase hematopoietic cell kinase (HCK), which is primarily expressed in the hematopoietic lineage but not in mature B cells, was aberrantly expressed in mantle cell lymphoma (MCL), and that high expression of HCK was associated with inferior prognosis of MCL patients.
1254621 YXEN2JIL items 1 apa default asc 1